Long-term efficacy of biologics in dermatology.
Chronic dermatologic diseases affect millions of people. The long-term nature of these diseases creates psychological and financial burden as well as substantially impacts patients' quality of life. Biologics, including adalimumab, etanercept, alefacept, efalizumab, and infliximab, are the newest therapeutic agents in the treatment of moderate-to-severe psoriasis and psoriatic arthritis and have been used in a variety of other dermatologic diseases. These agents act relatively quickly and effectively in 12-week clinical trials. Because these agents are used to treat patients for longer than 12 weeks, there is a need to review the safety and efficacy of these agents over longer periods of time. Many levels of evidence are available for biologics including high level of evidence from large, randomized, double-blind, placebo-controlled clinical studies. This review focuses on the available data for efficacy and safety for greater than 24 weeks of therapy. The studies supporting the use of rituximab and intravenous immunoglobulin in autoimmune blistering diseases are also presented in this review.
Castelo-Soccio
Leslie
L
Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA.
Van Voorhees
Abby S
AS
D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors
D001688:Biological Products; D003879:Dermatologic Agents